503b bulks list
5 Reasons FDA's Semaglutide Exclusion Will Cost You
The FDA’s exclusion of semaglutide from the 503B bulks list will increase GLP-1 dispensing costs by as much as 30% for most small practices. This policy shift removes a key cost-saving avenue and forces clinics to purchase finished-product vials at retail rates. Medical Disclaimer: This article is for informational